Predicting drug–drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning

References

• Zhang M, Zhang L, Hei R, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 2021 May 15;11(5):1913–1935. PMID: 34094661; PMCID: PMC8167670.
   PubMed Web of Science ®Google Scholar
• Sheikh MS, Satti SA. The emerging CDK4/6 inhibitor for breast cancer treatment. Mol Cell Pharmacol. 2021;13(3): 9–12. PMID: 35251463; PMCID: PMC8896653.
   PubMedGoogle Scholar
• Spring LM, Zangardi ML, Moy B, et al. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncology. 2017 Sep;22(9):1039–1048. Epub 2017 Jul 13. PMID: 28706010; PMCID: PMC5599204. doi: 10.1634/theoncologist.2017-0142
   Google Scholar
• Finn RS, Boer K, Bondarenko I, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020 Sep;183(2):419–428. doi: 10.1007/s10549-020-05755-7 Epub 2020 Jul 18. PMID: 32683565; PMCID: PMC7383036.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018 Nov 15;379(20):1926–1936. doi: 10.1056/NEJMoa1810527 Epub 2018 Oct 20. PMID: 30345905.
   PubMed Web of Science ®Google Scholar
• Finn RS, Boer K, Bondarenko I, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020;183(2):419–428. doi: 10.1007/s10549-020-05755-7
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. JCO. 2017;35(32):3638–3646.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Huober J, et al. LBA15 monarch 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (PTS) with HR+, HER2- advanced breast cancer (ABC). Annals Of Oncology. 2022 Sep;33:S1384. doi: 10.1016/j.annonc.2022.08.009
   Web of Science ®Google Scholar
• Rugo HS, Brufsky A, Liu X, et al. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer. NPJ Breast Cancer. 2022;8(1):114. doi: 10.1038/s41523-022-00479-x
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022 Mar 10;386(10):942–950. doi: 10.1056/NEJMoa2114663 PMID: 35263519.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–524. doi: 10.1056/NEJMoa1911149
   PubMed Web of Science ®Google Scholar
• Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–316. doi: 10.1056/nejmoa1903765
   PubMed Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116–124. doi: 10.1001/jamaoncol.2019.4782
   PubMed Web of Science ®Google Scholar
• Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5(5). doi: 10.1038/s41523-018-0097-z
   PubMedGoogle Scholar
• The ASCO Post. Abemaciclib plus AI in postmenopausal patients with advanced breast cancer: final overall survival analysis from monarch 3. The ASCO Post, [cited 2024 Feb 4]. Available from: ascopost.com/news/december-2023/abemaciclib-plus-ai-in-postmenopausal-patients-with-advanced-breast-cancer-final-overall-survival-analysis-from-monarch-3/
   Google Scholar
• Roncato R, Angelini J, Pani A, et al. CDK4/6 inhibitors in breast cancer treatment: potential interactions with drug, Gene, and pathophysiological conditions. Int J Mol Sci. 2020;21(17):6350. doi: 10.3390/ijms21176350.
   PubMed Web of Science ®Google Scholar
• Dagli RJ, Sharma A. Polypharmacy: a global risk factor for elderly people. J Int Oral Health. 2014 Nov;6(6):i–ii. PMID: 25628499; PMCID: PMC4295469
   Google Scholar
• Sun W, Klamerus KJ, Yuhas LM, et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with ph-dependent solubility, with different food intake conditions. Clin Pharmacol Drug Dev. 2017 Nov;6(6):614–626. doi: 10.1002/cpdd.356 Epub 2017 Apr 21. PMID: 28430398.
   PubMed Web of Science ®Google Scholar
• Çağlayan D, Koçak MZ, Geredeli Ç, et al. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer. Eur J Clin Pharmacol. 2023 Feb;79(2):243–248. doi: 10.1007/s00228-022-03435-7 Epub 2022 Dec 15. PMID: 36520173.
   PubMed Web of Science ®Google Scholar
• Del Re M, Omarini C, Diodati L, et al. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 2021 Oct;6(5):100231. Epub 2021 Sep 9. doi: 10.1016/j.esmoop.2021.100231 PMID: 34509802; PMCID: PMC8441157.
   PubMed Web of Science ®Google Scholar
• Samant TS, Dhuria S, Lu Y, et al. Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations. Clin Pharmacol Ther. 2018 Aug;104(2):374–383. doi: 10.1002/cpt.940. Epub 2017 Dec 8. PMID: 29134635; PMCID: PMC6099197.
   PubMed Web of Science ®Google Scholar
• Schieber T, Steele S, Collins S, et al. Effect of concurrent proton pump inhibitors with palbociclib tablets for metastatic breast cancer. Clin Breast Cancer. 2023 Aug;23(6):658–663. doi: 10.1016/j.clbc.2023.05.009 Epub 2023 May 24. PMID: 37296062.
   PubMed Web of Science ®Google Scholar
• Kaori T, Ryuji U, Toru M, et al. Proton pump inhibitors and cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer. Oncology. 2024;oyae015. doi: 10.1093/oncolo/oyae015
   Google Scholar
• Bellet M, Ahmad F, Villanueva R, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol. 2019 May 10;11:1758835919833867. doi: 10.1177/1758835919833867 PMID: 31205497; PMCID: PMC6535716.
   Web of Science ®Google Scholar
• Jones HM, Chen Y, Gibson C, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015 Mar;97(3):247–262. Epub 2015 Jan 9. doi: 10.1002/cpt.37 PMID: 25670209.
   PubMed Web of Science ®Google Scholar
• Streicher C, Daulange A, Madranges N, et al. Severe rhabdomyolysis induced by possible drug-drug interaction between ribociclib and simvastatin. J Oncol Pharm Pract. 2021 Apr;27(3):722–726. doi: 10.1177/1078155220945365 Epub 2020 Jul 29. PMID: 32727321.
   PubMed Web of Science ®Google Scholar
• Nelson KL, Stenehjem D, Driscoll M, et al. Fatal statin-induced rhabdomyolysis by possible interaction with palbociclib. Front Oncol. 2017 Jul 17;7:150. doi:10.3389/fonc.2017.00150 PMID: 28770167; PMCID: PMC5511828.
   PubMed Web of Science ®Google Scholar
• Nersesjan V, Hansen K, Krag T, et al. Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. BMC neurol. 2019 Oct 22;19(1):247. doi: 10.1186/s12883-019-1490-4 PMID: 31640597; PMCID: PMC6806583.
   PubMed Web of Science ®Google Scholar
• Fuentes AV, Pineda MD, Venkata KCN. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. Pharmacy (Basel). 2018 May 14;6(2):43. doi: 10.3390/pharmacy6020043 PMID: 29757930; PMCID: PMC6025009.
   PubMedGoogle Scholar
• Turner PK, Hall SD, Chapman SC, et al. Abemaciclib does not have a clinically meaningful effect on pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 substrates in patients with cancer. Drug Metab Dispos. 2020 Sep;48(9):796–803. doi: 10.1124/dmd.119.090092 Epub 2020 Jun 24. PMID: 32581049.
   PubMed Web of Science ®Google Scholar
• Kulanthaivel P, Mahadevan D, Turner PK, et al. (2016) Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors. In: Proceedings of the 107th Annual Meeting of the American Association of Cancer Research; 2016 Apr 16–20; New Orleans, LA: Vol 13, p. A586.
   Google Scholar
• Posada MM, Morse BL, Turner PK, et al. Predicting clinical effects of CYP3A4 modulators on abemaciclib and active metabolites exposure using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2020 Jul;60(7):915–930. doi: 10.1002/jcph.1584 Epub 2020 Feb 20. PMID: 32080863; PMCID: PMC7318171.
   PubMed Web of Science ®Google Scholar
• Samant TS, Huth F, Umehara K, et al. Ribociclib drug-drug interactions: clinical evaluations and physiologically-based pharmacokinetic modeling to guide drug labeling. Clin Pharmacol Ther. 2020 Sep;108(3):575–585. doi: 10.1002/cpt.1950 Epub 2020 Jul 25. PMID: 32557601.
   PubMed Web of Science ®Google Scholar
• Lagampan C, Poovorawan N, Parinyanitikul N. Lactic acidosis, a potential toxicity from drug–drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: a case report. Cancer Reports. 2022;5(8):e1575. doi: 10.1002/cnr2.1575
   Google Scholar
• LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Ribociclib. [cited 2018 May 8]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548818/
   Google Scholar
• Vuppalanchi R, Saxena R, Storniolo AMV, et al. Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib. Hepatology. 2017 May;65(5):1762–1764. doi: 10.1002/hep.28720 Epub 2016 Aug 9. PMID: 27397671.
   PubMed Web of Science ®Google Scholar
• Roncato R, Peruzzi E, Gerratana L, et al. Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure. Biomed Pharmacother. 2023 Aug;164:114906. doi: 10.1016/j.biopha.2023.114906 Epub 2023 Jun 7. PMID: 37295250.
   PubMed Web of Science ®Google Scholar
• Pfeiler G, Hlauschek D, Mayer EL, et al. Pallas groups and investigators. impact of BMI in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the pallas trial. J Clin Oncol. 2023 Nov 20;41(33):5118–5130. doi: 10.1200/JCO.23.00126 Epub 2023 Aug 9. PMID: 37556775.
   PubMed Web of Science ®Google Scholar
• Lampalo M, Ferara N, Jukić I et al. Blood neutrophils correlate with obesity in ASMATIC patients. Monitoring Airway Disease. 2019 Sep 28. doi: 10.1183/13993003.congress-2019.pa4274
   Google Scholar
• Franzoi MA, Eiger D, Ameye L, et al. Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy. J Natl Cancer Inst. 2021 Apr 6;113(4): 462–470. doi: 10.1093/jnci/djaa116 PMID: 32750143; PMCID: PMC8023855.
   PubMedGoogle Scholar
• Sorf A, Hofman J, Kučera R, et al. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochem Pharmacol. 2018 Aug;154:10–17. doi: 10.1016/j.bcp.2018.04.013 Epub 2018 Apr 16. PMID: 29673999.
   PubMed Web of Science ®Google Scholar
• Leenhardt F, Gracia M, Perrin C, et al. Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction. J Pharm Biomed Anal. 2020 Sep 5;188:113438. doi: 10.1016/j.jpba.2020.113438 Epub 2020 Jun 22. PMID: 32623316.
   PubMed Web of Science ®Google Scholar
• Leenhardt F, Fiteni F, Gauthier L, et al. Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects. Pharmaceutics. 2022 Apr 11;14(4):841. doi: 10.3390/pharmaceutics14040841 PMID: 35456675; PMCID: PMC9032884.
   PubMed Web of Science ®Google Scholar
• Roncato R, Gerratana L, Palmero L, et al. An integrated pharmacological counselling approach to guide decision-making in the treatment with cdk4/6 inhibitors for metastatic breast cancer. Front Pharmacol. 2022 Jul 22;13: 897951. doi: 10.3389/fphar.2022.897951 PMID: 35942220; PMCID: PMC9356076.
   PubMed Web of Science ®Google Scholar
• Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol. 2013 Aug 14;2(8):e63. doi: 10.1038/psp.2013.41 PMID: 23945604; PMCID: PMC3828005.
   PubMedGoogle Scholar